Cardiovascular imaging AI startup Corologic raises seed round from Kakao Ventures, SNU Holdings
What's the deal? CorologicDealroom has a profile for this one. Try Dealroom →, a South Korean medical AI startup, has raised an undisclosed seed round from Kakao Ventures and SNU Holdings. The company, founded in May by a team from Seoul National University Bundang Hospital's cardiology department, is building Angio-FILM, an AI tool that cuts radiation exposure during coronary angiography.
How it works: Coronary interventions rely on continuous X-ray imaging, exposing both patients and repeat-attending staff to radiation. Reducing image capture lowers that exposure but degrades frame rate and quality. Angio-FILM uses AI-based video frame interpolation to reconstruct low-frame angiography footage into high-frame imaging in real time, generating intermediate frames by analysing vessel and device movement.
Why it matters: The tool runs on existing angiography equipment via edge processing linked to hospital imaging systems, so hospitals adopt it without replacing hardware. That lowers the barrier to entry and keeps the product independent of any single device maker.
Who's behind it? Chief executive officer Hwang Kyung-rae brings 24 years in medical devices. Chief medical officer Kang Si-hyuck, a Bundang cardiology professor and interventional specialist, co-invented the core technology. Chief technology officer Choi Young-rak has developed angiography equipment and medical imaging AI.
What's the endgame? Corologic will use the funding to run multi-centre clinical validation and pursue regulatory clearances, including South Korea's Ministry of Food and Drug Safety, the US Food and Drug Administration's 510(k), and ISO 13485 certification. The startup completed a domestic medical device registration in August and demonstrated the product at EuroPCR 2026 in Paris in May.
What they're saying: Jung Joo-yeon, principal at Kakao Ventures, said the team developed technology that halves radiation "while maintaining image quality," calling it a "standalone solution" with global reach. Hwang said the goal is to build "a procedure environment that reduces radiation exposure" while giving clinicians the imaging they need.
The signal: The round reflects investor appetite for generative AI applied to clinical workflows, particularly tools that layer onto existing hospital infrastructure rather than requiring costly equipment overhauls — a model that could ease adoption across markets.
Read more: wowtale.net
Image credit: U.S. Navy Medicine
